NUP188 and uveal melanoma: In the disease-free interval (DFI), NUP188 played a risk role for patients with ACC, LGG, LIHC, MESO, sarcoma (SARC), SKCM, and uveal melanoma (UVM), but benefited the patients with KIRC and UCEC (Figure 3E).